Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 531

1.

Safety Profile of Thiopurines in Crohn Disease: Analysis of 893 Patient-Years Follow-Up in a Southern China Cohort.

Qiu Y, Mao R, Zhang SH, Li MY, Guo J, Chen BL, He Y, Zeng ZR, Chen MH.

Medicine (Baltimore). 2015 Oct;94(41):e1513. doi: 10.1097/MD.0000000000001513.

2.

Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma.

Yamazaki N, Kiyohara Y, Uhara H, Fukushima S, Uchi H, Shibagaki N, Tsutsumida A, Yoshikawa S, Okuyama R, Ito Y, Tokudome T.

Cancer Chemother Pharmacol. 2015 Nov;76(5):997-1004. doi: 10.1007/s00280-015-2873-x. Epub 2015 Sep 26.

3.

Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma.

Yamazaki N, Uhara H, Fukushima S, Uchi H, Shibagaki N, Kiyohara Y, Tsutsumida A, Namikawa K, Okuyama R, Otsuka Y, Tokudome T.

Cancer Chemother Pharmacol. 2015 Nov;76(5):969-75. doi: 10.1007/s00280-015-2870-0. Epub 2015 Sep 25.

4.

Chronic Responses of Daphnia magna Under Dietary Exposure to Leaves of a Transgenic (Event MON810) Bt-Maize Hybrid and its Conventional Near-Isoline.

Holderbaum DF, Cuhra M, Wickson F, Orth AI, Nodari RO, Bøhn T.

J Toxicol Environ Health A. 2015;78(15):993-1007. doi: 10.1080/15287394.2015.1037877.

5.

Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases.

Nomura K, Takahashi K, Hinomura Y, Kawaguchi G, Matsushita Y, Marui H, Anzai T, Hashiguchi M, Mochizuki M.

Drug Des Devel Ther. 2015 Jun 12;9:3031-41. doi: 10.2147/DDDT.S81998. eCollection 2015.

6.

Reactivation of hepatitis B (reverse seroconversion) after melphalan/dexamethasone therapy for primary amyloidosis: a case report.

Moon WR, Moon DS, Kim J, Yoon YM, Choi BS, Chung CH, Park SG.

J Med Case Rep. 2015 Jun 2;9:122. doi: 10.1186/s13256-015-0610-z.

7.

Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies.

Rixe O, Puzanov I, LoRusso PM, Cohen RB, Morris JC, Olowokure OO, Yin JY, Doroumian S, Shen L, Olszanski AJ.

Anticancer Drugs. 2015 Aug;26(7):785-92. doi: 10.1097/CAD.0000000000000250.

9.

Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome).

Pano A, Barbier AJ, Bielefeld B, Whiteman DA, Amato DA.

Orphanet J Rare Dis. 2015 Apr 24;10:50. doi: 10.1186/s13023-015-0265-2.

10.

Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.

Sehgal K, Das R, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru S, Ren Y, Wang M, Couto S, Breider M, Hansel D, Seropian S, Cooper D, Thakurta A, Yao X, Dhodapkar KM, Dhodapkar MV.

Blood. 2015 Jun 25;125(26):4042-51. doi: 10.1182/blood-2014-11-611426. Epub 2015 Apr 13.

11.

Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment.

Gozdas HT, Karabay O.

Indian J Pharmacol. 2015 Jan-Feb;47(1):121-2. doi: 10.4103/0253-7613.150377.

12.

Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials.

Hughes DA, Gonzalez DE, Lukina EA, Mehta A, Kabra M, Elstein D, Kisinovsky I, Giraldo P, Bavdekar A, Hangartner TN, Wang N, Crombez E, Zimran A.

Am J Hematol. 2015 Jul;90(7):584-91. doi: 10.1002/ajh.24012.

13.

Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial.

Brown JR, O'Brien S, Kingsley CD, Eradat H, Pagel JM, Lymp J, Hirata J, Kipps TJ.

Blood. 2015 Apr 30;125(18):2779-85. doi: 10.1182/blood-2014-12-613570. Epub 2015 Mar 13.

14.

Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2- locally advanced breast cancer.

Petry V, Gagliato DM, Leal AI, Arai RJ, Longo E, Andrade F, Ricci MD, Piato JR, Barroso-Sousa R, Hoff PM, Mano MS.

Braz J Med Biol Res. 2015 May;48(5):479-85. doi: 10.1590/1414-431X20144354. Epub 2015 Mar 6.

15.

Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.

Rossi-Semerano L, Fautrel B, Wendling D, Hachulla E, Galeotti C, Semerano L, Touitou I, Koné-Paut I; MAIL1 (Maladies Auto-inflammatoires et Anti-IL-1) study Group on behalf of CRI (Club Rhumatisme et Inflammation).

Orphanet J Rare Dis. 2015 Feb 15;10:19. doi: 10.1186/s13023-015-0228-7.

16.

Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial.

Schuind A, Segall N, Drame M, Innis BL.

J Infect Dis. 2015 Aug 15;212(4):531-41. doi: 10.1093/infdis/jiv091. Epub 2015 Feb 25.

17.

Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study.

Günther A, Baumann P, Burger R, Kellner C, Klapper W, Schmidmaier R, Gramatzki M.

Haematologica. 2015 Apr;100(4):541-7. doi: 10.3324/haematol.2014.116269. Epub 2015 Feb 14.

19.

GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6.

Rasche L, Duell J, Castro IC, Dubljevic V, Chatterjee M, Knop S, Hensel F, Rosenwald A, Einsele H, Topp MS, Brändlein S.

Haematologica. 2015 Mar;100(3):377-84. doi: 10.3324/haematol.2014.117945. Epub 2015 Jan 30.

20.

Safe and effective treatment of spontaneous neoplasms with interleukin 12 electro-chemo-gene therapy.

Cutrera J, King G, Jones P, Kicenuik K, Gumpel E, Xia X, Li S.

J Cell Mol Med. 2015 Mar;19(3):664-75. doi: 10.1111/jcmm.12382. Epub 2015 Jan 27.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk